End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.95 CNY | +2.35% |
|
+0.93% | -7.11% |
Jun. 27 | China Construction Bank Corporation Announces Board and Committee Changes | CI |
May. 16 | Bank of China Executive Vice President Steps Down | MT |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 64% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With an expected P/E ratio at 33.26 and 29.03 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.11% | 6.53B | C | ||
+7.40% | 101B | A- | ||
+7.76% | 42.18B | A- | ||
-14.37% | 32.26B | B- | ||
+80.74% | 29.79B | A | ||
-12.27% | 16.06B | C | ||
+2.33% | 14.45B | B- | ||
-8.56% | 12.01B | D+ | ||
+182.74% | 10.71B | D | ||
+4.19% | 8.89B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600161 Stock
- Ratings Beijing Tiantan Biological Products Co., Ltd.